Hunter Shkolnik discute de l'offre de $23 milliards de Teva
novembre 7, 2019
Source: Lecteur juridique
Teva Pharmaceutical Industries Ltd.’s proposed $23 billion drug giveaway over it’s suggesting to settle the opioid lawsuits against it will likely cost the company a fraction of that figure, according to industry experts. When Teva announced the value of the donated medicine – a generic version of opioid addiction treatment Suboxone – it based the figure on the drug’s list price, which does not account for significant discounts it will receive.